Article

Examining the Association Between Socioeconomic Status and Potential Human Papillomavirus-associated Cancers

Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia 30341, USA.
Cancer (Impact Factor: 4.9). 11/2008; 113(10 Suppl):2910-8. DOI: 10.1002/cncr.23742
Source: PubMed

ABSTRACT This study examined the association between county-level measures of socioeconomic status (SES) and the incidence rate of human papillomavirus(HPV)-associated cancers, including cervical, vulvar, vaginal, anal, penile, and oral cavity and oropharyngeal cancers.
The authors collected data from cancer registries for site-specific invasive cancer diagnoses between 1998 and 2003, inclusive, among adults aged >20 years at the time of diagnosis. County-level variables that included education, income, and poverty status were used as factors for socioeconomic status. Measures of rural-urban status, the percentage of the population that currently smoked, and the percentage of women who reported having ever had a Papanicolaou (Pap) test were also studied.
Lower education and higher poverty were found to be associated with increased penile, cervical, and vaginal invasive cancer incidence rates. Higher education was associated with increased incidence of vulvar cancer, male and female anal cancer, and male and female oral cavity and oropharyngeal cancers. Race was an independent predictor of the development of these potentially HPV-associated cancers.
These findings illustrate the association between SES variables and the development of HPV-associated cancers. The findings also highlight the importance of considering SES factors when developing policies to increase access to medical care and reduce cancer disparities in the United States.

Download full-text

Full-text

Available from: Nikki A Hawkins, Oct 06, 2014
0 Followers
 · 
149 Views
  • Source
    • "limited access to needed resources to mitigate the violence and address the health needs of victims (Breiding et al. 2008b; Cho 2012; Powers and Kaukinen 2012; Vest et al. 2002). They also have dramatically higher cervical cancer morbidity and mortality (Benard et al. 2008; US Cancer Statistics Working Group 2010). However, the literature has not explored the possibility that higher exposure and severity of IPValong with prolonged duration of IPVamong low-income, Black and Hispanic women may explain why these women suffer from dramatically higher morbidity and mortality rates of cervical cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this paper is to critically examine the literature and present a comprehensive model of three pathways through which IPV increases the risk for cervical cancer. The first pathway is increased exposure to cervical cancer risk factors among IPV victims, including smoking, psychosocial stress, risky sexual behaviors, and sexually transmitted infections (STDs/STIs), particularly human papillomavirus infection. The second pathway is poor compliance with cervical cancer screening. The third pathway is delay/discontinuation in treatment for cervical dysplasia and neoplasia. Control imposed by the abusive partner, competing life priorities, and limited access to financial/support resources restrict a woman’s ability to seek cancer services. Higher rates, severity, and duration of IPV among low-income, Black, and Hispanic women may explain the pervasive cervical cancer disparities.
    Journal of Family Violence 05/2015; DOI:10.1007/s10896-015-9733-7 · 1.17 Impact Factor
  • Source
    • "HPV vaccination rates are low among socioeconomic disadvantaged groups, and in states and regions with low cervical cancer screening participation and greater cervical cancer morbidity and mortality [8]. Uninsured and low-income women suffer disproportionate cervical cancer morbidity, mortality and late-stage diagnosis [9] [10]. Provider recommendation is a key facilitator to vaccination among low-income, medically underserved populations [11] [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the United States, Federally Qualified Health Centers (FQHCs) are safety-net clinics that provide cervical cancer screening and human papillomavirus (HPV) vaccination to medically underserved women, some of whom may be at risk for developing cervical cancer. National guidelines recommended against using screening test results or sexual history to determine vaccine eligibility. Documenting HPV vaccine recommendations and beliefs of primary care providers in FQHCs may aid in promoting evidence-based practices and prioritizing health interventions for vulnerable populations.
    Vaccine 08/2014; 32(42). DOI:10.1016/j.vaccine.2014.07.098 · 3.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This supplement, known as the ABHACUS (Assessing the Burden of HPV-Associated Cancers in the United States) supplement, contains 22 articles. Together, these articles provide a comprehensive snapshot of data related to the occurrence and control of multiple cancers that have been associated with the human papillomavirus (HPV). These analyses highlight the burden of HPV associated cancers in the US population as a whole and among vulnerable population subgroups. We anticipate that these findings will be an important resource for enhancing existing strategies for the prevention and control of HPV associated cancers. HPV is estimated to be responsible for 5.2% of the cancers diagnosed worldwide.1 Virtually 100% of cervical cancers are causally associated with HPV, and there is increasing evidence of the role that HPV plays in other anogenital cancers and oropharyngeal cancers. With the recent approval and recommendation of an HPV vaccine that contains HPV–16 and HPV–18, interest in quantifying the spectrum and burden of cancers is heightened. The International Agency for Research on Cancer (IARC) has determined that there is sufficient evidence for the carcinogenicity of HPV–16 in the cervix, vulva, vagina, penis, anus, oral cavity, and oropharynx.2 The IARC has found sufficient evidence of the role HPV–18 plays in cervical cancer, with limited or no evidence in other sites. Together, cervical cancer combined with the other HPV-associated cancers potentially afflicts an additional 25,000 persons every year in the US. Worldwide and in the US, the excitement and concern surrounding the HPV vaccine has been profound. The excitement derives from the potential of the vaccine to reduce the burden of cervical cancer in countries that have no screening infrastructure as well as in countries such as the US, in which nearly 11,000 women each year are told they have invasive cervical cancer and 4000 die from this disease, despite the availability of screening. The HPV vaccine also has the potential to impact a significant proportion of other cancers for which there typically is no routine screening. Conversely, the concern is that vaccine recipients may not continue to undergo screening for cervical cancer. Yet another concern is that if vaccine uptake is lower in those groups at highest risk of developing cervical cancer, current racial/ethnic or geographic disparities could increase. We hope that the articles in this supplement will highlight the burden and disparities associated with these cancers before vaccine implementation. This supplement includes an in-depth analysis of cancer incidence and mortality data from population- based central cancer registries that house highquality data. Fourteen articles are based mainly on cancer occurrence, using incidence data from population- based central cancer registries that participate in the Centers for Disease Control and Prevention (CDC)’s National Program of Cancer Registries (NPCR) and/or the National Cancer Institute (NCI)’s Surveillance, Epidemiology, and End Results (SEER) program. The NPCR program, which was established through the Cancer Registries Amendment Act passed by the US Congress in 1992, began providing financial support and technical assistance to population- based central cancer registries in 1994. This program currently supports central registries in 45 states, the District of Columbia, and 3 US territories; these registries cover approximately 96% of the US population. The SEER program, which was established as a result of the National Cancer Act of 1971, currently supports 14 such registries and 3 supplemental registries, covering approximately 26% of the US population. The population-based central cancer registries collect information on all reportable cancer cases within a state or another defined geographic area. Today, the NPCR and SEER programs together cover 100% of the US population, and data regarding more than 1 million new invasive cancer cases are added each year. Medical records are the primary source of the data. Both the NPCR and SEER data are collected and reported with the use of uniform data items and codes, as documented by the North American Association of Central Cancer Registries.3 The Institute of Medicine has recognized the importance of these 2 programs as valuable resources for studies on cancer.4
    Cancer 11/2008; 113(10 Suppl):2837-40. DOI:10.1002/cncr.23753 · 4.90 Impact Factor
Show more